Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27450

Keywords:

Abstract:

Source: